AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoeben, B. J.
Right arrow Articles by Williams, R. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoeben, B. J.
Right arrow Articles by Williams, R. O., III
Antimicrobial Agents and Chemotherapy, April 2006, p. 1552-1554, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1552-1554.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of Aerosolized Nanostructured Itraconazole Formulations for Prevention of Invasive Pulmonary Aspergillosis

Barbara J. Hoeben,1,3 David S. Burgess,1,3* Jason T. McConville,1 Laura K. Najvar,3 Robert L. Talbert,1,3 Jay I. Peters,3 Nathan P. Wiederhold,1,3 Bradi L. Frei,1,3 John R. Graybill,3 Rosie Bocanegra,3 Kirk A. Overhoff,1 Prapasri Sinswat,1 Keith P. Johnston,2 and Robert O. Williams III1

The University of Texas at Austin College of Pharmacy,1 The University of Texas at Austin College of Engineering,, Austin,2 The University of Texas Health Science Center at San Antonio, San Antonio,Texas3

Received 21 October 2005/ Returned for modification 18 November 2005/ Accepted 18 January 2006

Aerosolized evaporative precipitation into aqueous solution and spray freezing into liquid nanostructured formulations of itraconazole as prophylaxis significantly improved survival relative to commercial itraconazole oral solution and the control in a murine model of invasive pulmonary aspergillosis. Aerosolized administration of nanostructured formulations also achieved high lung tissue concentrations while limiting systemic exposure.

* Corresponding author. Mailing address: University of Texas Health Science Center at San Antonio, Clinical Pharmacy Programs-MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900. Phone: (210) 567-8329. Fax: (210) 567-8328. E-mail: burgessd{at}uthscsa.edu.

Antimicrobial Agents and Chemotherapy, April 2006, p. 1552-1554, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1552-1554.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.